Abstracts
Importance Cross-sectional assessment of epigenetic clocks provides information on the pace of aging. Whether longitudinal acceleration or deceleration of epigenetic clocks over time provides additional mortality prediction is unknown.
Objective To test the independent associations of baseline levels and longitudinal changes in epigenetic clocks with mortality
Design Longitudinal study
Setting InCHIANTI, a population-based study of community dwelling individuals in Tuscany, Italy.
Participants 699 InCHIANTI study participants aged 21-95 years at baseline with longitudinal measurements of DNA methylation.
Exposure Baseline levels and longitudinal changes in seven epigenetic clocks, including two first-generation clocks developed using chronological age for reference (Hannum Clock, Horvath Clock), three second-generation clocks developed using time-to-death for references (DNAmPhenoAge, DNAmGrimAge, DNAmGrimAge Version 2), and two third-generation clocks developed using longitudinal rate of change of multiple phenotypes for reference (DunedinPOAm_38, DunedinPACE).
Main Outcomes and Measures Mortality was the primary outcome. Cox regression was used to estimate independent associations of baseline and longitudinal changes in epigenetic clocks with mortality.
Results Adjusting for age, sex, study sites, and epigenetic clock at the baseline, longitudinal changes of the following epigenetic clocks were associated with mortality: Hannum clock (aHR = 1.14, 95% CI:[1.03, 1.26]), DNAmPhenoAge (aHR = 1.23, 95% CI: [1.10,1.37]), DNAmGrimAge (aHR = 1.13, 95% CI: [1.02,1.26]), DNAmGrimAge Version 2 (aHR = 1.18, 95% CI:[1.06,1.31]), and DunedinPOAm_38 (aHR = 1.15, 95%CI: [1.01,1.30]).
Conclusions and Relevance Our findings confirm that epigenetic clocks capture a dimension of health that is predictive of mortality and add the notion that time changes of epigenetic age reflect changes in health that additionally and independently contribute to mortality prediction. Future studies should test whether interventions that slow down the rate of epigenetic aging are associated with longer healthspan and lifespan.
Key Points Question: Is the rate of change in epigenetic clock associated with differential mortality?
Findings: In 699 adults with followed for up to 24 years, faster longitudinal changes in epigenetic clocks (Hannum clock, DNAmPhenoAge, DNAmGrimAge, DNAmGrimAge version 2, DunedinPOAm_38, DunedinPACE) were significantly associated with higher mortality, independent of baseline epigenetic age and other confounders.
Meaning: Independent of chronological age, epigenetic clock and change over time of epigenetic clock independently predicted the risk of death. Interventions that slow down the pace of epigenetic aging may enhance healthy longevity.
Competing Interest Statement
The work is supported by the Intramural Research Program of the National Institute on Aging. The Regents of the University of California is the owner of patent applications directed at epigenetic clocks for which SH and ATL are named inventors. SH is a founder and paid consultant of the nonprofit Epigenetic Clock Development Foundation that licenses these patents. DWB is an inventor of the DunedinPACE epigenetic clock, a Duke Univeristy and University of Otago invention licensed to TruDiagnostic. He is consulting CSO and SAB chair of BellSant and an SAB member of the Hooke Clinic. P-LK, AZM, TT, SB, and LF declare no conflict of interests. DWB is a fellow of the CIFAR CBD Network (CIFAR is the Canadian Institute for Advanced Research. CBD stands for Child Brain Development.). This work utilized the computational resources of the NIH HPC Biowulf cluster. (http://hpc.nih.gov)
Clinical Protocols
https://www.nia.nih.gov/inchianti-study#access
Funding Statement
The work is supported by the Intramural Research Program of the National Institute on Aging. The Regents of the University of California is the owner of patent applications directed at epigenetic clocks for which SH and ATL are named inventors. SH is a founder and paid consultant of the nonprofit Epigenetic Clock Development Foundation that licenses these patents. DWB is an inventor of the DunedinPACE epigenetic clock, a Duke Univeristy and University of Otago invention licensed to TruDiagnostic. He is consulting CSO and SAB chair of BellSant and an SAB member of the Hooke Clinic. P-LK, AZM, TT, SB, and LF declare no conflict of interests. DWB is a fellow of the CIFAR CBD Network (CIFAR is the Canadian Institute for Advanced Research. CBD stands for Child Brain Development.). This work utilized the computational resources of the NIH HPC Biowulf cluster. (http://hpc.nih.gov)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The InCHIANTI study participants were recruited from two Chianti regions of Tuscany, Italy, (1998 to 2000). For the present analysis, we included 699 participants with DNA methylation measurements measured at two follow-up or more timepoints (in the 1998, 2007, and 2013 study visits). InCHIANTI was approved by the Italian National Institute of Research and Care of Aging Institutional Review Board and study participants provided informed consents.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
“The InCHIANTI database is available to any researcher who presents a detailed and scientifically sound project. Data available through InCHIANTI cover a range of factors that influence walking ability that are classified into the six subsystems listed above. Measures of the integrity and functioning of each of these subsystems were identified and administered to all participants.” Link to access: “https://www.nia.nih.gov/inchianti-study#access”
